SCROLL DOWN
NeuroVita-Lab Inc. is a specialized research-driven organization dedicated to overcoming degenerative central nervous system (CNS) diseases and sarcopenia. By leveraging advanced disease-specific animal models, we lead the development of innovative therapies and provide scientific solutions to address the complexities of brain aging.
NeuroVita-Lab Inc. develops proprietary adeno-associated virus (AAV) gene therapy platforms for the treatment of neurodegenerative and movement disorders. By integrating optimized AAV delivery with disease-specific expression control technology, we enable precise, stable, and long-term therapeutic gene expression in the CNS. Our approach addresses key limitations of existing treatments and establishes a new paradigm for durable gene therapies in Parkinson’s disease and other major movement disorders.
Age-related sarcopenia represents a significant unmet medical and societal need. NeuroVita-Lab Inc. focuses on the discovery and validation of novel functional bio-actives that improve and sustain muscle function, enabling the development of scientifically substantiated health functional foods and therapeutic solutions.
NeuroVita-Lab provides robust efficacy and safety evaluations for drug candidates using a comprehensive portfolio of animal models with neurodegenerative diseases. We design and execute customized preclinical studies to enable rapid, accurate validation of candidate compounds. As a trusted and efficient partner, we help accelerate drug development and reduce time to market for novel therapies.
NeuroVita-Lab Inc. aims to extend the healthy human lifespan and enhance the quality of life through innovative therapeutics and functional food research for neurodegenerative diseases and sarcopenia. Alongside our internal R&D, we offer non-clinical CRO services to support the efficient development of new drug candidates.
INQUIRY
